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Introduction
Laparoscopic surgery was initially developed in France
and the USA. It was originally referred to as laser surgery
since lasers were used for parts of the dissection. This
type of surgery is associated with significantly more
benefits than conventional laparotomy. It leads to little
blood loss, short hospital stay, quick recovery, less need
for analgesia, rapid return to normal daily activity, and
better cosmetic appearance [1,2]. Laparotomy
commonly paralyzes bowel function (known as ileus),
which is rarely seen after laparoscopic surgery. Early
experience with laparoscopic surgery in gynecology
was gained mainly through female sterilization by
laparoscopic tubal ligation in the 1970s [3]. Significant
improvements in surgical skill and instrumentation over
the last decade, including video monitoring technology
in the late 1980s that evolved until abdominal content
could be projected onto TV screens, have stretched the
application of laparoscopy beyond a secondary diag-
nostic role and transformed it into a primary assisting
component of gynecologic surgery. Since many gyneco-
logic malignancies require complicated procedures, pro-
jection of a relatively small area in selected regions of the
abdomen enables better management of the disease
during laparoscopic surgery. It is now possible to perform
increasingly complex surgical procedures using video
monitor laparoscopy, avoiding major surgery. Today,
laparoscopic surgery refers to a minimally invasive
procedure in a very focal area of the abdomen without
a large incision that results in minimal formation of scar
tissue. Unlike imaging methods such as X-ray, computed
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tomography (CT), magnetic resonance imaging (MRI),
and ultrasound, laparoscopic surgery allows direct
observation of the abdomen and pelvis. It has become
a popular and widespread technique accepted by gyne-
cologists as an appropriate alternative to conventional
surgery in the management of patients with gynecologic
disease [4].
Despite its many advantages over standard lapa-
rotomy, the role of laparoscopic surgery has been
controversial for managing patients with gynecologic
malignancies. Although laparoscopy offers better
visualization during surgery, the lack of tactile feedback
and loss of depth perception have frustrated many
gynecological oncologists who are familiar with con-
ventional laparotomy [2]. Many have not developed
laparoscopic skills because of the lack of opportunity,
the lack of standardization of the laparoscopic tech-
niques, and increased frustration in the learning process.
Different laparoscopic procedures are also associated
with different degrees of learning, from a relatively
simple laparoscopically assisted radical vaginal hys-
terectomy (LARVH) to the more difficult Schauta
operation. Some gynecologic oncologists have been
somewhat hesitant because the effectiveness of
laparoscopic procedures compared with standard
abdominal procedures has not been established by
prospective randomized trials [5]. Others are concerned
with the risk of port-site metastases, which have been
reported in patients with early malignancies [6]. From
the first documentation of laparoscopic lympha-
denectomy by Dargent in 1987 [7] to the comparison of
LARVH with abdominal radical hysterectomy (ARH) by
Steed et al in 2004 [8], long-term follow-up and com-
parative studies have highlighted the use of modern
laparoscopy in the field of gynecologic oncology. It is
clear that, after more than 10 years of experience with
laparoscopic procedures, laparoscopic surgery is appro-
priate for several gynecologic malignancies. This
paper reviews recent reports and updates information
on current practice in laparoscopic pelvic and paraaortic
lymphadenectomy for the management of cervical
cancer.
Laparoscopic Pelvic and Paraaortic
Lymphadenectomy
Cervical cancer is the second most common gynecologic
malignancy in the world, but the most prevalent genital
tract neoplasm in Taiwan [9]. Although many factors
have been studied and correlated with patient outcome
in various staging systems and classifications, the In-
ternational Federation of Gynecology and Obstetrics
(FIGO) staging system is the most common classification
system used by major medical centers across the world
for the clinical diagnosis of patients with cervical cancer.
Generally speaking, surgical staging is superior to clinical
staging since histologic verification of tumor extent
correlates better with the biologic behavior of the disease
[10]. Lymphatic dissemination of tumor cells is one of
the main metastatic routes of cervical cancer. Lymphatic
metastases follow a relatively predictable ascending
pattern [11], appearing first in the pelvic lymph nodes
and spreading to the aortic lymph nodes. The presence
of lymph node metastases (pelvic or paraaortic) is the
most significant prognostic factor that determines
recurrence and survival in patients with early cervical
cancer [12]. Nodal metastases in gynecologic malig-
nancies have an unfavorable impact on survival in
patients with early and advanced cervical cancer. Aortic
node sampling is particularly critical in the assessment
of advanced cervical cancer compared with early disease.
Surgical-pathologic staging is the only reliable method
for evaluation of pelvic and aortic lymph nodes and can
be performed as a pretreatment assessment, as part of
surgical procedures, or as reassessment of inadequately
staged patients. However, a major shortcoming of
surgical staging by laparotomy is its association not
only with high morbidity and prolonged recovery, but
also with development of postoperative peritoneal
adhesions. Peritoneal adhesions are responsible for the
high incidence of post-irradiation enteric morbidity
during radiotherapy, and are a critical concern for
patients with advanced disease. Laparoscopic staging
is an alternative in the surgical-pathologic staging of
patients with cervical cancer. The major attribute of lapa-
roscopic surgery is its association with fewer post-
operative peritoneal adhesions, which is particularly
critical for pretreatment assessment of patients with
advanced disease to define the extent of disease spread.
Laparoscopic lymphadenectomy, either partial (lymph
node sampling) or complete lymphadenectomy, leads
to minimal postoperative peritoneal adhesions and
permits accurate assessment of the extent of disease in
cervical patients with early or advanced disease. Laparo-
scopic pelvic and paraaortic lymphadenectomy have
emerged as a new surgical technique that can potentially
replace conventional surgical staging by laparotomy.
History
The laparoscopic management of cervical cancer has
been evolving over the last 18 years. The progression of
laparoscopic technique is documented in works pub-
lished by many clinicians, addressing various aspects of
laparoscopic lymphadenectomy and its clinical roles.
The published experience with laparoscopic lympha-
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denectomy for surgical staging in patients with cervical
cancer is summarized in Tables 1 and 2. Laparoscopic
lymphadenectomy is generally combined with radical
or vaginal hysterectomy in a curative approach (Table
1); very few cases have been reported of staging alone
(Table 2). The use of laparoscopy for pelvic and para-
aortic lymph node dissections are the subject of
considerable debate in relation to its complications.
Although both pelvic and paraaortic lymph node dis-
sections have been used in some studies, information
concerning operating time and complications are not
available separately for the two procedures. It is a
challenging task to assess the specific role of laparo-
scopic lymphadenectomy in the surgical-pathologic
staging of patients with cervical cancer when it is
performed as part of other surgical procedures.
Early disease
Dargent reported the first use of laparoscopic lym-
phadenectomy in early disease in 1987 [7]. The 3-year
survival rate was 95.5% in 51 patients with negative
pelvic nodes. This alternative, to dissect lymph nodes
laparoscopically, opened up new perspectives for gyne-
cologic oncology. Dargent incorporated laparoscopic
retroperitoneal pelvic lymphadenectomy (LRPL) in
Schauta radical hysterectomy. However, laparoscopic
transperitoneal pelvic lymphadenectomy (LTPL),
developed subsequently by Querleu et al in 1991 as
a transperitoneal counterpart [13], replaced LRPL as
the standard technique in pelvic lymph node sampling.
Although the transperitoneal approach is associated
with a longer learning process, is less easy, and has more
limitations than LRPL, it offers a better view and reduced
hematoma and lymphocyst formation than LRPL [33].
The feasibility of using transperitoneal laparoscopy for
paraaortic lymphadenectomy (laparoscopic trans-
peritoneal paraaortic lymphadenectomy, LTPAL) was
demonstrated by Childers et al the following year [14].
Querleu reported a series of eight patients, demon-
strating less blood loss, shorter hospital stay, and
decreased pain with LARVH and LTPL than with ab-
dominal surgery [18]. Hatch et al reported their
experience in 37 patients treated using LARVH and
LTPL [20]. Mean blood loss was 525 mL (range, 200–
1,400 mL) and average hospital stay was 3 days (range,
2–11 days). Roy et al compared postoperative com-
plications of radical vaginal and radical abdominal
hysterectomies after laparoscopic pelvic lympha-
denectomy [21]. After laparoscopic pelvic lymphaden-
ectomy in 52 patients, 25 underwent radical vaginal
hysterectomy and the other 27 underwent radical
abdominal hysterectomy. Blood loss, operative time,
and blood transfusion were comparable in the two
groups. Schneider’s group has published extensively on
laparoscopic nodal dissection and has maintained
prospective data for 10 years, from which significant
information is available [23,27,28,34]. Kohler et al
compiled the largest series to date of laparoscopic
pelvic and/or paraaortic nodal dissections [28]. Trans-
peritoneal lymphadenectomy was performed in 650
patients between August 1994 and September 2003.
Most cases (396/650, 61%) were related to cervical
cancer: staging of advanced cervical cancer (133/396,
34%); trachelectomy for early cervical cancer (42/396,
11%); and LARVH (221/396, 56%). The authors
concluded that the complication rate of both LTPL
and LTPAL was low and could be minimized by stan-
dardization of the procedure. Nevertheless, this study
evaluated the complication rate in all 650 patients,
including more than one cancer type. A more precise
understanding of the complications involved in lapa-
roscopic lymphadenectomy for cervical cancer was pro-
vided by Hertel et al [27], who reported the largest series
of LARVH, comprising 200 patients with cervical cancer
(FIGO stage IA1–IV) between August 1994 and June
2002. Not only did they report both short- and long-
term complications of the procedure, they also correlated
the clinical pathologic data with long-term survival
data. Laparoscopic pelvic and/or paraaortic nodal
dissections were performed in all 200 patients. The
major contribution of this publication was the pro-
posal of selection criteria for LARVH: ideal candidates
were patients with tumor size less than 4 cm, negative
lymph nodes, and no angio-lymph vascular involvement.
Patients with stage IIB disease or greater are typically
not considered candidates for radical hysterectomy in
the USA: stage IIB (45/200, 23%), stage IIIA (1/200,
0.5%), and stage IV (1/200, 0.5%). The recognized
higher complication rate of radical surgery with radiation
therapy and the effectiveness of chemoradiation therapy
in randomized controlled trials have precluded patients
with IB2 disease and above from surgery in the USA [12,
35,36]. Hertel et al’s paper was the first to provide the
same clinical pathologic data for LARVH comparable to
the Gynecologic Oncology Group (GOG) study [35]
and the study by Alvarez et al [12] for radical surgery.
This study supports that the high-risk parameters for
recurrence following radical hysterectomy are also
important in LARVH. After a median follow-up of 40
months, the overall 5-year survival was projected to be
83%. An excellent projected 5-year survival of 98% for
110 patients can be achieved using the proposed
selection criteria for ideal patients followed by indicated
adjuvant therapy. However, no explanation was given as
to why 29 of these 110 patients (26%) received adjuvant
radiotherapy. The study by Hertel et al provides the best
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evidence to support LARVH as being equally effective
as radical abdominal hysterectomy and open lympha-
denectomy in the management of cervical cancer.
Advanced disease
Patients with advanced disease (FIGO stage IIB or
higher) are often clinically staged without surgical
assessment. The risk of extended-field radiotherapy
(EFRT) is an additional factor to consider when assess-
ing the complication rate and accuracy of laparosco-
pic diagnostic procedures for patients with advanced
disease. Such patients are usually treated with
chemotherapy, irradiation, or a combination of both.
Chemoradiation is, in general, limited to the pelvis for
these patients. Since EFRT can be associated with
significant gastrointestinal tract and other morbidities,
it is used only if there is evidence of paraaortic lymph
node involvement [37,38]. The risk of grade 3 or 4
toxicities, mainly gastrointestinal tract and urinary
complications, following prophylactic paraaortic
irradiation in randomized controlled trials is 4% [39,
40]. The presence and extent of metastases in the
common iliac and paraaortic nodes directly influences
clinical decisions [41,42]. There is a high incidence of
paraaortic lymph node metastasis in advanced disease:
6% in stage IB, 12–19% in stage II, 29–33% in stage III,
and 30–40% in stage IV disease [43]. Unfortunately, the
evaluation of lymphatic spread with currently available
noninvasive cross-sectional imaging modalities such as
lymphography, CT, MRI, and guided fine-needle
aspiration is associated with relatively poor sensitivity
and specificity [42]. Understaging of up to 30–50% of
advanced disease cases using clinical methods has been
reported [44]. Conventional CT or MRI provides a
sensitivity and specificity near 80% when nodes are
greater than 1 cm, but this falls to 24% with smaller
lymph nodes [45,46], which are found in many patients
with advanced disease. Moreover, these lymph nodes
often do not show signs of enlargement or distortion,
which makes diagnosis even more difficult. The apparent
discrepancy between clinical staging and surgical-
pathologic findings clearly delineates the significance of
surgical assessment for patients with advanced disease.
Surgical staging by laparoscopy and negative nodes
on preoperative CT in advanced cervical cancer (stage
IIB or greater) were pioneered by Childers et al [14] as
an appropriate alternative to avoid some of these
complications. These authors found no significant short-
term complications. However, other authors have
reported that CT is inaccurate. Goff et al reported that
it was necessary to modify the standard pelvic radiation
field in 43% of patients with locally advanced disease
after surgical staging [47]. Vergote et al also found no
suspicious nodes on CT in 38 advanced-stage patients
(stages IB2–IIIB in this study) who underwent lower
paraaortic lymphadenectomy, while laparoscopic
evaluation detected microscopic paraaortic metastases
in 18% of patients (7/38) [48]. Possover et al reported
that frozen section was an indispensable component of
laparoscopic evaluation that could correctly identify all
patients with involved lymph nodes [34]. The addition
of frozen section to laparoscopic evaluation led to a
change in primary therapy in 15.4% of cases, and the
laparoscopy–frozen section combination achieved a
sensitivity and specificity of 92.3%. Considering the high
accuracy and specificity of the laparoscopy–frozen
section combination as well as the minimal complication
rate, it seems reasonable to recommend the use of
laparoscopic surgery for staging of advanced patients
before radiation therapy.
Postoperative peritoneal adhesions
The ability to prevent postoperative peritoneal adhe-
sions is the impetus behind the ongoing investigation
into laparoscopic surgery. Adhesion formation limits the
mobility of intestinal loops and exposes them to excess
irradiation. This outstanding feature of laparoscopy is
extremely significant in the management of uterine
cancer because patients subjected to radiotherapy after
lymphadenectomy are considered at risk for recurrence.
Patients with cervical cancer could benefit from less
traumatic surgery, potentially enabling a faster recovery
and early administration of postoperative adjuvant
chemotherapy and radiotherapy. Lanvin et al provided
evidence of the benefit of laparoscopic dissection and
its association with significantly fewer adhesions than
transperitoneal laparotomy (anterior abdominal wall,
p = 0.0006; paraaortic area, p = 0.0005; right iliac area,
p = 0.015; left iliac area, p = 0.0324) [49]. Querleu et al
reported that pelvic adhesions were not observed in 32
patients undergoing laparotomy up to 6 weeks after
LTPL [13]. An animal study by Fowler et al also showed
less adhesion formation after LTPL when compared
with retroperitoneal laparotomy [50]. Leblanc et al
conducted a retrospective comparative study of 26
patients, and discovered six severe complications among
patients irradiated after laparotomic pelvic dissection
and only one complication after laparoscopic dissection
[51]. These studies clearly demonstrate the absence of
significant postoperative complications after laparo-
scopic surgery.
Approach of laparoscopic paraaortic lymph node
dissection
Randomized studies have not been performed to com-
pare the three approaches to laparoscopic paraaortic
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lymph node dissection (transperitoneal, bilateral ret-
roperitoneal, and left retroperitoneal), and it is diffi-
cult to compare the results from different studies. The
major technical disadvantage of the transperitoneal
approach is the difficulty in exposing the left paraaortic
area during nodal dissection. The retroperitoneal
approach is technically easier, surgically and anatomic-
ally more logical, and creates fewer peritoneal adhe-
sions with fewer resultant bowel complications than its
transperitoneal counterpart [52]. It is generally accepted
that retroperitoneal aortic dissection reduces the risk of
radiation enteritis. Unlike its transperitoneal counter-
part, the retroperitoneal approach provides rapid access
to the paraaortic lymph node dissection area. Laparo-
scopic retroperitoneal paraaortic lymphadenectomy
(LRPAL) allows accurate detection of micrometastases
in the paraaortic nodes, allowing more precise selection
of patients with advanced cervical cancer for EFRT and
precluding patients from overtreatment. LRPAL can be
performed through a bilateral iliac incision or through
a unilateral left incision. The first available publication
on LRPAL was by Vasilev and McGonigle [53], followed
by papers by Dargent et al [54], Querleu et al [55], and
Mehra et al [56] (Table 3). Dargent et al, in a retrospective
study, extended LRPL to the retroperitoneal dissection
of the common iliac and aortic nodes [54]. They reported
that all three approaches to laparoscopic paraaortic
lymph node dissection were able to retrieve similar
numbers of nodes. Moreover, the mean duration of the
total operation, complication rate, and hospital stay
were also comparable. The authors confirmed the feasi-
bility of the left retroperitoneal route for systematic
paraaortic lymph node sampling for patients with cer-
vical cancer, but recommended the bilateral approach
when facing difficulties in the left side approach. Since
LRPL was designed primarily for the removal of inter-
iliac nodes, it does not allow adequate intraperitoneal
exploration and aortic lymphadenectomy [13,57,58].
It has been commented that this novel technique has
gained the acceptance of Querleu et al [59], the pio-
neers of LTPL, in 2003. The major complication of this
technique is the formation of giant lymphocysts, which
can be avoided by incision of the peritoneum of the
paracolic gutter at the end of the procedure, allowing
intraperitoneal drainage of the retroperitoneal dissection
area.
Numbers of retrieved lymph nodes
The adequacy of laparoscopic pelvic and paraaortic
lymphadenectomy is the subject of considerable debate.
Various numbers of retrieved lymph nodes have been
reported (Tables 1 and 2). Seventeen studies are sum-
marized in Table 1 in an attempt to provide an overview
of the various techniques that have been combined with
laparoscopic lymphadenectomy between 1991 and
2004. Since patients with early disease are mostly curable,
lymph node dissections are often combined with various
other curative surgical techniques (Table 1). Conversely,
only patients with advanced disease require pretreatment
laparoscopic staging (Table 2). Only nine studies are
available for laparoscopic staging alone within the same
period, and data on retrieved lymph nodes are available
for only eight studies. Paraaortic lymphadenectomies
are performed to determine the extent of disease spread
so that appropriate chemo/radiotherapy can be tailored
for advanced disease patients. A few early studies
between 1991 and 1994 reported inadequate numbers
of retrieved pelvic lymph nodes (Table 1), including
Querleu et al [13], Nezhat et al [15], Querleu et al [18],
and Dargent et al [19], who reported an average of
only 8.7, 14, 12.6, and 13.4 lymph nodes, respectively.
However, many other investigators have provided suf-
ficient evidence that laparoscopic lymphadenectomy
is capable of adequately identifying all positive lymph
nodes and removing sufficient lymph nodes for adequate
staging. The exclusion of the four cases with inadequate
retrieval from Table 1 yields an average of 25 retrieved
pelvic lymph nodes (range, 18.3–35.5), which is com-
parable to the number recovered at laparotomy [14,16,
22,23,32,60].
Childers et al published the first description of LTPAL
in patients with cervical cancer [14]. Su et al published
the first series in which adequacy of LTPAL was confirmed
by standard laparotomy [31]. This series comprised 36
cases of laparoscopic paraaortic lymphadenectomy
and 21 comparative laparotomies. Chu et al reported
28 cases of LTPAL, 28 cases of LTPAL followed by ARH,
and six cases of LARVH [22]. Lecuru et al also retrieved
matching numbers of lymph nodes in their study in 33
fresh cadavers, comparing pelvic lymphadenectomy
performed by unilateral laparoscopy and contralateral
laparotomy [61]. Dargent et al also retrieved similar
mean numbers of nodes using all three approaches
to laparoscopic paraaortic lymph node dissection
(transperitoneal, bilateral retroperitoneal, left retro-
peritoneal) [54], which were comparable or even high-
er than in laparotomy as reported by Buchsbaum [62]
and Finan et al [63].
A GOG study in multiple centers evaluated laparo-
scopic retroperitoneal lymphadenectomy in women with
early cervical cancer (Table 2) [32]. The surgical sites
were inspected at laparotomy (radical hysterectomy)
immediately after LRPL and LRPAL. The objectives of
the study were to examine the adequacy of lymph node
removal, and the adverse effects and difficulties as-
sociated with laparoscopic lymph node dissection.
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Although 67 patients underwent laparoscopy, only
40 (60%) conformed to all study parameters. These
40 patients constituted the core of the study. Mean
operating time was 209 minutes (range, 90–465 min-
utes). The mean number of retrieved pelvic nodes was
32.1 (16.6 on the left and 15.5 on the right) and that
of aortic nodes was 12.1 (5.9 on the left and 6.2 on
the right). The results of LRPL were judged inadequate
in six of the 40 patients (15%), but the residual nodes,
mainly in the lateral common iliac area, did not contain
metastases. Laparoscopic complications were evaluated
in all 67 patients. There were seven major vessel injuries
(10.4%) and one ureteral vessel injury (1.5%). Three of
the major vessel injuries required conversion to laparo-
tomy for bleeding control, a conversion rate of 4.5%.
Since laparotomy was subsequently performed in all
cases, there was no way to evaluate the benefits or
detriments of laparoscopic lymph node removal in
relation to hospital stay, blood loss, or postoperative
complications. This study demonstrated that LRPAL is
a safe and feasible procedure by all methods of evalua-
tion (i.e. blinded review of video prints or video tape and
surgeon opinion at laparotomy). The authors judged
that the complication rate associated with LRPL could
probably be improved. Although more radical aortic
lymphadenectomy has been advocated by some centers
to achieve a higher node count, there is no evidence that
increased radicalism translates into higher cure rates
[64]. Even in obese patients, approximately equal
numbers of pelvic and paraaortic nodes were obtained
by LTPL and LTPAL as at laparotomy. Laparoscopic
lymphadenectomy has been regarded as contrain-
dicated in obese patients, especially those requiring
LTPAL [65]. Since obese patients can make LTPL and
LTPAL more difficult, most studies have limited their
patients to either the weight range of 180–210 pounds
or a body mass index (BMI) of less than 30 [22,23,31,
65]. Although obesity is regarded as the most limiting
factor in successful paraaortic lymphadenectomy, the
number of nodes yielded is comparable to that obtained
at laparotomy. The largest reported series of obese
patients showed an overall success rate of 82.1% in
patients with a BMI of less than 35, and 44.4% success
rate in patients with a BMI above 35 [66]. Kohler et al,
in their retrospective study of 650 patients, confirmed
that LTPL and LTPAL were independent of BMI, with an
adequate number of lymph nodes removed in an
adequate time [28].
Extent of paraaortic dissection
LRPAL to sample common iliac and aortic nodes is the
principal technique for patients with advanced cervical
cancer [33]. However, the extent of aortic dissection is
still extensively debated. There is no doubt that extending
the upper limit of dissection increases dissection time.
Querleu et al reported that the aortic field can be pre-
cluded from treatment if common iliac and aortic nodes
are negative by the retroperitoneal approach [59].
Positive nodes were suggested to be an important
prognostic factor for high-risk patients and a critical
indicator of distant metastases and death. The authors
suggested that further staging is essential for patients
with positive aortic nodes, including positron emission
tomography and scalene node biopsy. Patients with
positive nodes and no identified distant metastases
were suggested to be candidates for EFRT with con-
current chemotherapy. Few published studies have
indicated the feasibility of surgical-pathologic staging
by laparoscopy in advanced cervical cancer, so pro-
spective clinical trials and long-term follow-up are
required to justify the safety of pre-irradiation laparo-
scopic staging in patients with advanced cervical
carcinoma. Marchiole and Dargent believe that aortic
dissection is not required if the pelvic lymph nodes are
not involved (risk of aortic involvement < 1%) [67].
Inframesenteric dissection alone is adequate in 75% of
all cases of aortic metastases. Vergote et al reduced the
operating time from 120–150 minutes to 70 minutes by
omitting the supramesenteric portion of the procedure
[48]. They reported an 18% (7/38) positive rate for
lymph node dissection limited to the inferior mesenteric
artery. When aortic dissection must be performed,
Marchiole and Dargent [67] and Querleu et al [33,59]
suggest that the dissection must be performed up to the
level of the left renal vein. Michel et al provided evidence
of patients with positive lymph nodes in the left infrarenal
area [68]. Querleu et al found a 23% positive rate in a
series of 133 patients when dissection was extended to
the renal vessels [33,59].
Training in laparoscopic lymphadenectomy
The ability to perform laparoscopic lymphadenectomy
with minimal complications depends primarily on the
surgeon. Querleu et al performed 542 pelvic lymph
node dissections via LTPL without a single conversion to
laparotomy as a result of complications [33]. Marchiole
and Dargent advised that visceral and vascular injuries
would be less frequent with pelvic lymph node dissection
using LTPL from their series of 25 cases [67]. The recent
study by Frumovitz et al demonstrated the difficulty of
training physicians in advanced laparoscopic surgical
skills [5]. They recruited 393 subjects to determine the
proportion of Society of Gynecologic Oncologists (SGO)
members who were able to perform laparoscopic pro-
cedures, and to determine their opinions regarding
indications for, and the adequacy of training in, lapa-
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roscopy. The recruited subjects included 336 SGO
members (85%) and 57 fellows (15%). They had limited
laparoscopic training during their fellowships, where
39% received no training and 46% received limited
training (< 5 procedures/month). Nevertheless, 78% of
the SGO members (262) and 25% of the fellows (14)
rated their laparoscopic skills as being either very good
or good. Most SGO members (269, 80%) considered at
least six procedures per month as being necessary for
adequate training, but only a minority of fellows (19,
33%) performed that many procedures. As a whole,
most fellows perceived their laparoscopic training to be
inadequate.
Conclusion
More than 10 years of experience with laparoscopic
procedures have allowed gynecologic oncologists to
devise therapeutic methods for the management of
cervical cancer. Although the feasibility, safety, and
adequacy of laparoscopic surgery are not entirely clear,
cumulative evidence demonstrates the clinical role of
laparoscopic lymphadenectomy in the management
of patients with cervical cancer. Many patients with
early and advanced cervical cancer may benefit from
laparoscopic staging, evaluation, treatment, or a com-
bination. The mean number of pelvic and paraaortic
nodes retrieved laparoscopically is similar to that
obtained at laparotomy, even in obese patients. The
intraoperative benefits of the laparoscopic technique
include minimal blood loss, less adhesion formation,
and better visual perspective. The risk of recurrence and
overall survival are equivalent to those achieved with
laparotomy. Intraoperative injuries are recognized and
repaired laparoscopically during surgery. Only a small
percentage of cases require conversion to laparotomy,
and significant long-term postoperative complications
are infrequent. The multicenter GOG study shows
promising results with laparoscopic retroperitoneal
lymphadenectomy in staging and treatment in women
with early cervical cancer. These benefits include mini-
mal discomfort, shorter hospitalization, and quicker
recovery, which have a positive impact on a patient’s
quality of life. Moreover, the ability to prevent post-
operative peritoneal adhesion marks the superiority
of surgical staging by laparoscopy over laparotomy.
Adhesion formation can often lead to higher radiation
risks for patients during postoperative adjuvant radio-
therapy. Surgical staging by laparoscopy is certainly
attractive to patients with advanced disease in that they
can avoid a laparotomy before initiating definitive
chemotherapy and irradiation. There is no question
that the complication rate of laparoscopic lympha-
denectomy using both transperitoneal and retro-
peritoneal approaches is extremely low in the hands
of experienced gynecologic oncologists. Laparoscopic
surgery should be performed by experts and surgeons
accredited in these fields until further results from
prospective clinical trials such as GOG become available.
This literature review should convince readers that
the wide spread of laparoscopic pelvic and paraaortic
lymphadenectomy in the management of cervical cancer
is to be expected in the near future. A major limitation
is the difficulty of training physicians in advanced
laparoscopic surgical skills. The lack of tactile feedback
and loss of depth perception have frustrated many
gynecologic oncologists who are familiar with conven-
tional laparotomy. Since laparoscopic lymphaden-
ectomy in the surgical-pathologic staging of patients
with cervical cancer is often performed as part of other
surgical procedures, the lack of new protocols for the
different operations in use is a challenge. Nonetheless,
it is the author’s belief that laparoscopic lymphaden-
ectomy will soon be an alternative for surgical staging of
gynecologic cancers.
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